776 related articles for article (PubMed ID: 26366797)
1. Treatment of the genitourinary syndrome of menopause.
Palacios S; Mejía A; Neyro JL
Climacteric; 2015; 18 Suppl 1():23-9. PubMed ID: 26366797
[TBL] [Abstract][Full Text] [Related]
2. Safety and efficacy of ospemifene for the treatment of dyspareunia associated with vulvar and vaginal atrophy due to menopause.
Wurz GT; Kao CJ; DeGregorio MW
Clin Interv Aging; 2014; 9():1939-50. PubMed ID: 25419123
[TBL] [Abstract][Full Text] [Related]
3. Genitourinary Syndrome of Menopause.
Shifren JL
Clin Obstet Gynecol; 2018 Sep; 61(3):508-516. PubMed ID: 29787390
[TBL] [Abstract][Full Text] [Related]
4. Ospemifene: a novel selective estrogen receptor modulator for treatment of dyspareunia.
Eder SE
Womens Health (Lond); 2014 Sep; 10(5):499-503. PubMed ID: 25335541
[TBL] [Abstract][Full Text] [Related]
5. Ospemifene for the treatment of vulvovaginal atrophy and dyspareunia in postmenopausal women.
McLendon AN; Clinard VB; Woodis CB
Pharmacotherapy; 2014 Oct; 34(10):1050-60. PubMed ID: 25052122
[TBL] [Abstract][Full Text] [Related]
6. What's new in the world of postmenopausal sex?
Iglesia CB
Curr Opin Obstet Gynecol; 2016 Oct; 28(5):449-54. PubMed ID: 27517339
[TBL] [Abstract][Full Text] [Related]
7. Ospemifene: A Novel Oral Therapy for Vulvovaginal Atrophy of Menopause.
Reid RL; Black D; Derzko C; Portman D
J Obstet Gynaecol Can; 2020 Mar; 42(3):301-303. PubMed ID: 31932249
[TBL] [Abstract][Full Text] [Related]
8. Genitourinary syndrome of the menopause--dawn of a new era?
Panay N
Climacteric; 2015; 18 Suppl 1():13-7. PubMed ID: 26366795
[TBL] [Abstract][Full Text] [Related]
9. Treating vulvovaginal atrophy/genitourinary syndrome of menopause: how important is vaginal lubricant and moisturizer composition?
Edwards D; Panay N
Climacteric; 2016 Apr; 19(2):151-61. PubMed ID: 26707589
[TBL] [Abstract][Full Text] [Related]
10. BMS - Consensus statement.
Pitkin J;
Post Reprod Health; 2018 Sep; 24(3):133-138. PubMed ID: 30244644
[TBL] [Abstract][Full Text] [Related]
11. Ospemifene: a first-in-class, non-hormonal selective estrogen receptor modulator approved for the treatment of dyspareunia associated with vulvar and vaginal atrophy.
DeGregorio MW; Zerbe RL; Wurz GT
Steroids; 2014 Nov; 90():82-93. PubMed ID: 25087944
[TBL] [Abstract][Full Text] [Related]
12. Treatment of dyspareunia secondary to vulvovaginal atrophy.
Fantasia HC
Nurs Womens Health; 2014; 18(3):237-41. PubMed ID: 24939201
[TBL] [Abstract][Full Text] [Related]
13. Update on management of genitourinary syndrome of menopause: A practical guide.
Palacios S; Castelo-Branco C; Currie H; Mijatovic V; Nappi RE; Simon J; Rees M
Maturitas; 2015 Nov; 82(3):308-13. PubMed ID: 26261035
[TBL] [Abstract][Full Text] [Related]
14. A cost-effectiveness analysis of vaginal carbon dioxide laser therapy compared with standard medical therapies for genitourinary syndrome of menopause-associated dyspareunia.
Wallace SL; St Martin B; Lee K; Sokol ER
Am J Obstet Gynecol; 2020 Dec; 223(6):890.e1-890.e12. PubMed ID: 32562659
[TBL] [Abstract][Full Text] [Related]
15. Ospemifene for the treatment of postmenopausal vulvar and vaginal atrophy: recommendations for clinical use.
Pinkerton JV; Kagan R
Expert Opin Pharmacother; 2015; 16(17):2703-14. PubMed ID: 26634778
[TBL] [Abstract][Full Text] [Related]
16. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
J Sex Med; 2014 Dec; 11(12):2865-72. PubMed ID: 25155380
[TBL] [Abstract][Full Text] [Related]
17. Genitourinary syndrome of menopause: new terminology for vulvovaginal atrophy from the International Society for the Study of Women's Sexual Health and the North American Menopause Society.
Portman DJ; Gass ML;
Menopause; 2014 Oct; 21(10):1063-8. PubMed ID: 25160739
[TBL] [Abstract][Full Text] [Related]
18. Pharmacokinetics, pharmacodynamics and clinical efficacy of ospemifene for the treatment of dyspareunia and genitourinary syndrome of menopause.
Bondi C; Ferrero S; Scala C; Tafi E; Racca A; Venturini PL; Leone Roberti Maggiore U
Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1233-46. PubMed ID: 27476551
[TBL] [Abstract][Full Text] [Related]
19. Management of symptomatic vulvovaginal atrophy: 2013 position statement of The North American Menopause Society.
Menopause; 2013 Sep; 20(9):888-902; quiz 903-4. PubMed ID: 23985562
[TBL] [Abstract][Full Text] [Related]
20. [Local estrogen therapy--clinical implications--2012 update].
Kokot-Kierepa M; Bartuzi A; Kulik-Rechberger B; Rechberger T
Ginekol Pol; 2012 Oct; 83(10):772-7. PubMed ID: 23383564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
